Assessing Risk Factors for Relapse Following Omalizumab Discontinuation in Chronic Urticaria
Allergy · 2025-05 · 80 (5) · 1495-1497
DOI: 10.1111/all.16458 ↗At a glance
Leserbrief in Allergy, published online on 2024-12-26. Written by Melek Cihanbeylerden and 7 co-authors. Institution: Department of Pulmonology, Division of Allergy and Clinical Immunology, Hacettepe University Hospital, Ankara, Turkey. Cited 3 times so far (Crossref); 6 references.
Abstract (original language)
Intet abstract tilgængeligt.
Authors and institutions
- Department of Pulmonology, Division of Allergy and Clinical Immunology, Hacettepe University Hospital, Ankara, Turkey.
- Department of Dermatology and Venereology, University Hospital, Coimbra Local Health Unit, Coimbra, Portugal.
- Faculty of Medicine, University of Coimbra, Coimbra, Portugal.
ORCID profiles: Melek Cihanbeylerden, João Teixeira, Ebru Damadoglu, Margarida Gonçalo
Cite
APA
Cihanbeylerden, M., Teixeira, J., Kayıkçı, H., Tüccar, Ç., Kalyoncu, A. F., Damadoglu, E., Gonçalo, M., & Karakaya, G. (2025). Assessing Risk Factors for Relapse Following Omalizumab Discontinuation in Chronic Urticaria. Allergy, 80(5), 1495-1497. https://doi.org/10.1111/all.16458
Vancouver
Cihanbeylerden M, Teixeira J, Kayıkçı H, Tüccar Ç, Kalyoncu AF, Damadoglu E, et al. Assessing Risk Factors for Relapse Following Omalizumab Discontinuation in Chronic Urticaria. Allergy. 2025;80(5):1495-1497. doi:10.1111/all.16458
BibTeX
@article{Cihanbeylerden2025,
author = {Cihanbeylerden, Melek and Teixeira, João and Kayıkçı, Hazal and Tüccar, Çise and Kalyoncu, Ali Fuat and Damadoglu, Ebru and Gonçalo, Margarida and Karakaya, Gül},
title = {Assessing Risk Factors for Relapse Following Omalizumab Discontinuation in Chronic Urticaria},
journal = {Allergy},
year = {2025},
volume = {80},
number = {5},
pages = {1495--1497},
doi = {10.1111/all.16458}
}
EUVIMED